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Background: Microbial/bacterial resistance against antibiotics poses a serious threat to public health. Furthermore,
the side effects of these antibiotics have stimulated tremendous interest in developing new molecules from diverse
organisms as therapeutic agents. This study evaluates the antibacterial potential of a basic protein, Vipera russellii
venom phospholipase A2 fraction VIIIa (VRV-PL-VIIIa), from Daboia russelii pulchella venom against gram-positive and
gram-negative bacteria.
Methods: The antibacterial potential of VRV-PL-VIIIa in the presence and absence of an inhibitor (p-bromophenacyl
bromide) was tested against gram-positive and gram-negative bacteria and the minimum inhibitory concentration
was determined by microdilution tests.
Results: VRV-PL-VIIIa demonstrated potent antibacterial activities against all the human pathogenic strains tested. It
more effectively inhibited such gram-positive bacteria as Staphylococcus aureus and Bacillus subtilis, when compared
to the gram-negative bacteria Escherichia coli, Vibrio cholerae, Klebsiella pneumoniae and Salmonella paratyphi. It
inhibited bacterial growth at minimum inhibitory concentration values ranging from 11.1 to 19.2 μg/mL. The
anti-bacterial potential of VRV-PL-VIIIa was comparable to the standards gentamycin, chlorophenicol and streptomycin.
The PLA2’s hemolytic and antibacterial activities were strongly correlated. Furthermore, even in the presence of
p-bromophenacyl bromide, intense antibacterial activity was observed, suggesting a dissociation or partial
overlapping of the bactericidal/antimicrobial domains.
Conclusion: VRV-PL-VIIIa demonstrated potent antibacterial activities against all the human pathogenic strains tested.
The study shows that despite a strong correlation between enzymatic and antimicrobial activities of VRV-PL-VIIIa, it may
possess additional properties that mimic the bactericidal/membrane permeability-increasing protein. This study
encourages further in-depth studies on the molecular mechanisms of antibacterial properties of VRV-PL-VIIIa,
which would thereby facilitate development of this protein into a possible therapeutic lead molecule for treating
bacterial infections.
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Microbial/bacterial resistance against antibiotics consti-
tutes a therapeutic problem that poses a significant threat
to public health [1–4]. The prevalence of bacterial resist-
ance to conventional antibiotics has prompted an intense
search for new therapeutic agents from diverse animal ori-
gins [5]. Proteins/peptides with potent antimicrobial activ-
ities are found in many secretions of organisms, including
snakes [5, 6]. Venoms from snakes, particularly Crotalidae,
are known to be a rich natural source for the discovery
and development of novel antimicrobial agents [6, 7].
Among the various components of snake venom, phospo-
holipase A2 (svPLA2) enzyme, apart from its catalytic
activity of hydrolyzing the sn-2 ester bond of glyceropho-
spholipids, shows other important toxic/pharmacologic
effects that include myonecrosis, neurotoxicity, cardio-
toxicity, as well as hemolytic, hemorrhagic, hypertensive,
anticoagulant, platelet-aggregation-inhibiting and edema-
inducing activities [8, 9]. This array of biological actions
may be either dependent or independent of catalytic activ-
ities. The svPLA2s are also reported to act as antimicrobial
agents and are emphasized for their potential as thera-
peutic lead molecules [6, 7]. Crotapotin, a secretory
phospholipase A2 isolated from the venom of Crotalus
durissus terrificus, has been demonstrated to exert anti-
bacterial activity as well as antiviral activity against the
human immunodeficiency virus [10–12]. Acidic PLA2s,
both Asp49 and Lys49 PLA2 homologues, have previously
been shown to perform bactericidal activity [13–15]. A
cationic protein isolated from venom of the inland taipan
(Oxyuranus microlepidotus) has been demonstrated to
selectively and dose-dependently kill the gram-positive
bacteria through membrane disruption [16]. Recently, a
phospholipase A2 from the venom of the saw-scaled viper
with novel bactericidal and membrane-damaging activities
was characterized [17]. These molecules are shown to be
highly attractive due to their biochemical diversity, and
broad spectrum of activity against enveloped bacteria,
fungi, viruses, protozoa, and parasites [6, 7, 18].
Despite the therapeutic potential of svPLA2s as anti-
microbial agents, very few with bactericidal/antimicro-
bial activities have been characterized [6, 18, 19]. Found
in India, Russell’s viper (Daboia russelii) is a widely dis-
tributed snake responsible for potent toxic and lethal ef-
fects [20–23]. Despite several reports on its various
biological effects, relatively little is known regarding its
antimicrobial activity [20–25]. Furthermore, there are no
reports available in relation to the antimicrobial activity
exhibited by PLA2s from the venom of Daboia russelii
pulchella. A basic PLA2, namely Vipera russellii venom
phospholipase A2 fraction VIIIa (VRV-PL-VIIIa), isolated
from Daboia russelii pulchella venom is reported to pro-
voke various biological effects such as edema, platelet
aggregation, pulmonary hemorrhage etc. [26, 27]. In thepresent work, we evaluate the antibacterial potential of
VRV-PL-VIIIa and investigate its possible biochemical
mechanism of action. Additionally, this study exemplifies
the therapeutic utility of VRV-PL-VIIIa as an antimicro-
bial agent.
Methods
Venom of Daboia russelii pulchella (Southern region)
was purchased from the Irula Co-operative Society Ltd.
(India). Agar, beef extract, yeast extract and peptone
were bought from Hi Media Private Ltd. (India). The
p-Bromophenacyl bromide (p-BPB) and other chemicals
used were all of analytical grade and purchased from
Sigma Chemicals Ltd. (USA). Authentic pure clinical
isolated cultures of human pathogenic bacteria –
Staphylococcus aureus, Bacillus subtilis, Escherichia coli,
Salmonella typhi, Vibrio cholerae, Klebsiella pneumoniae
and Salmonella paratyphi – were obtained from the
Department of Microbiology, Adichunchanagiri Institute
of Medical Sciences (AIMS), B.G. Nagara, Karnataka,
India. These are all human pathogens that have developed
some resistance to common antibiotics particularly in the
clinical environment. Bacteria were multiplied in nutrient
agar at 36 ± 2 °C. After 2 days, cultures were harvested
and prepared at a final concentration of 1 × 108 cfu/mL
and used for the in vitro inhibition assay.
Isolation of VRV-PL-VIIIa and chemical modification by
p-Bromophenacyl bromide
VRV-PL-VIIIa from the venom of Daboia ruselii pulchella
was purified until homogeneous as described previously
by the method of Kasturi and Gowda [26], with modifica-
tions by Srinivasan [27]. The protein concentration was
estimated by Lowry’s method. Chemical modification of
PLA2 by p-Bromophenacyl bromide (p-BPB) was carried
out as described by Condrea et al. [28]. Briefly, 100 μL of
40 mM p-BPB in acetone was added to 3 mL of PLA2
solution (0.5 mg/mL, in 0.05 M Tris–HCl buffer, pH 7.5).
The reaction was allowed to proceed for 40 min, and then
acidified with glacial acetic acid to pH 4.0 to stop the reac-
tion. Excess of reagent was removed by dialyzing against
0.05 M Tris–HCl buffer pH 7.5.
Phospholipase A2 activity
The phospholipase A2 assay was carried out according
to the method described by Bhat and Gowda [29]. Phos-
phatidyl choline (PC) was diluted with petroleum ether
(60–80 °C) to obtain a concentration of 1000 nmoles/
50 mL. The reaction mixture containing VRV-PL-VIIIa
(5 μg) was augmented to 680 μL with water. To the
reaction mixture, 200 μL of ether, 100 μL of Tris–HCl
buffer (0.05 M, pH 7.5) and 20 μL of CaCl2 (0.4 M) were
added. The total reaction mixture was incubated at 37 °C
for 60 min. After incubation, 0.5 mL of Dole’s mixture
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mixed and centrifuged at 1000 rpm for 3 min. To the
organic phase, 0.5 mL of CHCl3:pet ether (1:5) was
added, mixed and centrifuged at 1000 rpm for 3 min.
To the upper phase, cobalt reagent [1.35 vol. of trietha-
nolamine increased to 10 mL with solution A (6 g of
CO(NO3)2.6H2O + 0.8 mL glacial acetic acid) and 7 mL
of solution B (saturated Na2SO4)] was added, mixed
and centrifuged 1000 rpm for 3 min. The upper organic
phase was carefully transferred and 0.75 mL of α-nitroso-
β-naphthol reagent (0.4 % α-nitroso-β-naphthol in 96 %
ethanol) was added. The intensity of the orange coloration
is directly proportional to the amount of cobalt present.
After 30 min, 2 mL of ethanol was added to dilute the
contents and absorbance was read at 540 nm. The amount
of free fatty acid released was estimated using the standard
linolenic acid curve. The enzyme activity was expressed as
nmoles of fatty acid released/minute/mg of protein.
For inhibition studies, VRV-PL-VIIIa (5 μg) was pre-
incubated with or without a different concentration of
p-Bromophenacyl bromide (1–6 μm) at 37 °C for
15 min. Appropriate controls were set up and further
experiments were performed as described above. The
inhibition is expressed as a percentage, considering the
activity of venom alone as 100 %.
Hemolytic activity assay
Hemolytic (direct/indirect) activity of isolated VRV-PL-
VIIIa was determined according to the method of
Boman and Kaletta [30], using packed human erythro-
cytes (blood group A). The human erythrocytes used for
the study were sourced from previously published work,
which had ethical approval from the ethics committee of
the University of Mysore (UOM) for the withdrawal of
blood [23]. The direct and indirect hemolytic assays
were carried out using washed erythrocytes. For the dir-
ect hemolytic assay, the packed erythrocytes (1 mL) were
suspended in nine volumes of phosphate-buffered saline
(PBS), which formed the stock. The stock (1 mL) was
incubated with various concentrations of isolated VRV-
PL-VIIIa (0–5 μg) for 30 min at 37 °C. For the indirect
hemolytic assay, stock was prepared by mixing packed
erythrocytes (1 mL), egg yolk (1 mL) and phosphate-
buffered saline (8 mL). One milliliter of suspension from
stock was incubated with various concentrations of iso-
lated VRV-PL-VIIIa (0–6 μg) for 30 min at 37 °C. The
reaction was terminated by adding 10 mL of ice-cold PBS
and then centrifuged at 4 °C and 800 g. The amount of
hemoglobin released in the supernatant was measured at
540 nm. One milliliter of stock erythrocytes with 10 mL
ice-cold PBS alone was defined as constituting 0 % lysis.
For inhibition studies, VRV-PL-VIIIa (6 μg) was pre-
incubated with or without a different concentration of
p-Bromophenacyl bromide (1–6 μM) at 37 °C for15 min. Appropriate controls were set up and further
experiments were accomplished as described above. The
inhibition is expressed as a percentage, considering the
activity of venom alone as 100 %.
Bactericidal activity of VRV-PL-VIIIa
Bactericidal activity was evaluated by the well diffusion
method on nutrient agar medium [31]. This was con-
firmed by the inhibitory effect on bacterial growth as
reflected by the inhibition zone, compared to that of
known antibiotics such as gentamicin (G), chloram-
phenicol (Cp) and streptomycin (Sm) at 30 μg/mL. The
sterile nutrient agar medium (20 mL) in petri dishes
was uniformly smeared using sterile cotton swabs with
pure test cultures of the human pathogenic bacteria
S. aureus, B. subtilis, E. coli, S. typhi, V. cholerae, K.
pneumoniae and S. paratyphi. The nutrient agar media
was prepared by dissolving 0.3 % beef extract, 0.3 %
yeast extract, 0.5 % peptone, 0.5 % NaCl and 1.5 % agar
in 1:l of distilled water and 0.2 % methanol (v/v). The
wells of 5 mm diameter were made using a sterile cork
borer in each petri dish and the isolated VRV-PL-VIIIa
(0-12 μg) pre-incubated independently with or without
p-Bromophenacyl bromide (15 μM) was added; a blank
well loaded without test compound was considered the
control. For each treatment, ten replicates were prepared.
The plates were incubated at 37 °C for 24 h and the result-
ing zone of inhibition was measured by comparing the
control and the standard antibiotics.
For inhibition studies, VRV-PL-VIIIa (12 μg) was pre-
incubated with or without a different concentration of
p-Bromophenacyl bromide (1–6 μM) at 37 °C for
15 min and antimicrobial activity was assessed as de-
scribed above with appropriate controls. The inhibition
is expressed as a percentage, considering the activity of
venom alone as 100 %.
Determination of minimum inhibitory concentration (MIC)
The minimum inhibitory concentration of the isolated
VRV-PL-VIIIa and the antibiotics used were determined
by serial dilution in the nutrient agar, with concentra-
tions ranging from 2–20 μg/mL. The inoculum was pre-
pared overnight from fresh broth culture in nutrient
broth and plates were incubated for 24 h at 37 °C. MIC
was recorded as the lowest VRV-PL-VIIIa at which the
antibiotic concentrations demonstrated no visible growth
in the broth [32].
Statistical analysis
Statistical analysis was done using the software SPSS
(Windows version 10.0.1; SPSS Inc., USA) employing a
one-way Student’s t test; p < 0.05 was considered as statis-
tically significant when compared with relevant controls.
All results are presented as mean ± SD.
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The snake venom PLA2s (svPLA2s), apart from their
well known toxic and lethal effects, are also known to
be of therapeutic utility, particularly as bactericidal/
antibacterial agents [6, 19]. In a previous study, it was
shown that the crude Russell’s viper venom from India
exhibited strong antibacterial actions [25]. However, the
principal component responsible for it was unexplored.
In the present work, we evaluate the basic PLA2 (VRV-
PL-VIIIa) of Daboia russelii pulchella venom for its
antibacterial activity on different human pathogenic
bacteria [26, 27].Fig. 1 a Dose-dependent bactericidal activity of VRV-PL-VIIIa against different
diffusion assays. The diameter of the clear zone was measured and plotted af
for three independent assays, each performed in triplicate. b Dose-dependen
strains – V. cholerae, K. pneumonia, S. paratyphi – in agar diffusion assays. The
the diameter of the well (5 mm). Results are mean ± SD for three independenWhen tested, VRV-PL-VIIIa (0–12 μg/mL) showed a
broad spectrum of highly significant antibacterial activities
by producing a clear zone of inhibition that was dose-
dependent in the range of 17–30 mm (Fig. 1 – a and b)
(Table 1). Interestingly, it showed more significant inhib-
ition of gram-positive bacteria including S. aureus and
B. subtilis (in the range of 27–32 mm) in relation to
such gram-negative species as E. coli, S. typhi, V.
cholerae, K. pneumoniae and S. paratyphi (in the range
of 16–22 mm) (Table 1). Furthermore, it was
interesting to note that VRV-PL-VIIIa exhibited similar
or greater antibacterial activities than those of thehuman pathogenic strains – S. aureus, E. coli, B. subtilis, S. typhi – in agar
ter subtracting the diameter of the well (5 mm). Results are mean ± SD
t bactericidal activity of VRV-PL-VIIIa against different human pathogenic
diameter of the clear zone was measured and plotted after subtracting
t assays, each performed in triplicate
Table 1 Antibacterial activity of VRV-PL-VIIIa and standard
antibiotics
Microorganisms Diameter of inhibition zone (mm)
VRV-PL-VIIIa Ga Cpa Sma
Gram-positive
Staphylococcus aureus 32 ± 1 18 ± 1 23 ± 2 26 ± 2
Bacillus subtilis 27 ± 4 18 ± 2 19 ± 2 28 ± 3
Gram-negative
Escherichia coli 21 ± 2 18 ± 2 18 ± 2 21 ± 2
Salmonella typhi 16 ± 1 17 ± 2 18 ± 1 18 ± 1
Vibrio cholerae 16 ± 3 16 ± 2 19 ± 2 19 ± 2
Klebsiella pneumoniae 22 ± 2 18 ± 2 18 ± 1 21 ± 3
Salmonella paratyphi 21 ± 6 19 ± 2 18 ± 2 20 ± 2
The results are mean ± SD (n = 6)
Standard antibioticsa G gentamicin, Cp chloramphenicol, Sm streptomycin
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(which was in the range of 16–20 mm) (Table 1). When
VRV-PL-VIIIa was tested via the agar dilution assay for
determining minimum inhibitory concentration (MIC),
it significantly inhibited the bacterial growth with MIC
values ranging from 11.2 to 20 μg/mL, when compared
to standard antibiotics whose range was between 18
and 24 μg/mL (Table 2). Thus, VRV-PL-VIIIa was as
potent as standard antibiotics in inhibiting the growth
of bacterial strains.
A strong correlation is usually found between the
PLA2’s hemolytic and antibacterial activities [6, 19, 25].
The VRV-PL-VIIIa also showed a potent hemolytic
(indirect) activity that is usually associated with svPLA2s.
It was found that VRV-PL-VIIIa produces a dose-
dependent hemolysis of blood cells and at 5 μg concentra-
tion provoked 100 % hemolysis (Fig. 2). From these data it
may be concluded that the antibacterial effects of VRV-
PL-VIIIa are dependent upon catalytic activity, i.e., anTable 2 Minimum inhibitory concentration (MIC) of VRV-PL-VIIIa
and standard antibiotics by serial dilution method
Microorganisms MIC (μg/mL)
VRV-PL-VIIIa G Cp Sm
Gram-positive
Staphylococcus aureus 15.3 ± 1 20.8 ± 1 14.4 ± 2 13.6 ± 1
Bacillus subtilis 11.1 ± 3 20.8 ± 3 14.4 ± 1 16.6 ± 1
Gram-negative
Escherichia coli 16.3 ± 2 23.8 ± 1 14.4 ± 2 14.6 ± 1
Salmonella typhi 17.2 ± 2 18.8 ± 1 17.4 ± 2 13.6 ± 1
Vibrio cholerae 17.3 ± 2 19.8 ± 3 14.4 ± 1 19.6 ± 1
Klebsiella pneumoniae 19.2 ± 1 20.8 ± 1 14.4 ± 2 13.6 ± 1
Salmonella paratyphi 17.3 ± 2 23.8 ± 1 14.4 ± 2 14.6 ± 1
The results are mean ± SD (n = 6)
G gentamicin, Cp chloramphenicol, Sm streptomycinenzymatic membrane degradation effect that is usually
observed in sPLA2s [6, 33]. The correlation between
PLA2, hemolytic and antibacterial activities indicates that
the catalytically activity of PLA2 is principally involved in
bactericidal/antibacterial activities [6, 19, 25]. However,
despite the existence of another mechanism, namely
svPLA2 isolated from Bothrops asper (also classified within
group IIA) venom, which was shown to directly kill both
gram-positive and gram-negative bacteria [13].
Furthermore, a toxin from B. asper (myotoxin II, a
catalytically inactive Lys49 PLA2) exhibited a bactericidal
mechanism that was independent of catalytic activity
[13, 6, 19]. Additional in-depth studies showed that a
short sequence of the protein, corresponding to residues
115–129 of its cytolytic C-terminal region, was respon-
sible for its bactericidal activity, emphasizing the fact
that bactericidal activity is not associated with enzymatic
activities [6, 13, 19]. Similarly, the study found that when
VRV-PL-VIIIa was pre-incubated with p-BPB, an inhibitor
of svPLA2 enzymatic activity, both enzymatic and antibac-
terial activities were inhibited (Fig. 3 and Table 3) [34].
However, it should be noted that there was incomplete
abolition of antibacterial activity (Table 3), even though
the enzymatic activity was completely abolished (Table 4).
This suggests a dissociation between enzymatic activity
and bactericidal/antibacterial activity of VRV-PL-VIIIa. It
is usually observed that the potent bactericidal activity of
sPLA2s is accomplished by binding to anionic surfaces
along with the enzymatic degradation of phospholipids in
the target membranes, i.e., preferentially in the case of
gram-positive species. However, the bactericidal activity
against gram-negatives is known to require a synergistic
action of bactericidal/permeability-increasing protein
(BPI), and is also equally dependent on enzymatic-based
membrane degradation [13, 6, 17, 19].
It has been demonstrated that, in addition to cationic
properties of PLA2 molecules, the polyanionic properties
of lipoteichoic acids from bacterial cell wall promote the
attack of membrane phospholipids by svPLA2s. There-
fore, the action mode of svPLAs depends on the type of
bacteria species involved (gram-positive or negative).
Recently, an association was shown between antibacter-
ial and enzymatic activity of an antibacterial PLA2
(EcTx-I) purified from Echis carinatus venom [6]. How-
ever, the present study found that the bactericidal activity
of VRV-PL-VIIIa is partially independent of catalytic activ-
ity and antibacterial activities (Tables 3 and 4), which is
supported by the homogenous nature of the protein
with no other associated enzymatic activities (such as
L-amino-oxidase, proteases etc.) in the preparation
(data not shown). Therefore, the VRV-PL-VIIIa bacteri-
cidal mechanism may include “fatal depolarization” of
the bacterial membrane, creation of physical holes in
the membrane, scrambling of normal distribution of
Fig. 2 Dose-dependent indirect hemolytic activity of VRV-PL-VIIIa. VRV-PL-VIIIa (0–5 μg) in 100 μL of phosphate-buffered saline (PBS) was incubated
with erythrocytes, egg yolk and PBS (1:1:8 v/v) for 10 min at 37 °C. The released hemoglobin in the supernatant was measured by reading absorbance
at 540 nm. The results are expressed as ± S.E.M. (n = 4)
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intracellular targets after internalization of the peptide,
and also inhibition of macromolecular biosynthesis as
observed in many svPLA(2)s and/or interaction with
specific vital components inside the bacteria [6, 35].
It was reported that PLA2s purified from Agkistrodon
piscivorus piscivorus rely on a membrane-permeabilizing
mechanism to exert their bactericidal effects [36]. A
recent study showed the presence of a large number of
PLA2-sensitive phospholipid domains/composition,Fig. 3 Bactericidal activity against different human pathogenic strains of VR
VRV-PL-VIIIa (12 μg/mL) was pre-incubated with or without a different conc
bactericidal activity was estimated in agar diffusion assay. The diameter of the
the well (5 mm). Results are expressed as mean ± SD for three independent arather than only the phosphatidylcholine (PC) content
of a particular membrane that determines the extent of
membrane damage by a particular venom PLA2 enzyme
[37]. This might be one of the reasons for the differen-
tial inhibitory potency of VRV-PL-VIIIa on various
bacterial species. Therefore, it may be concluded that
the isolated VRV-PL-VIIIa phospholipase A2, will mani-
fest its antimicrobial activity not only by acting upon
the membrane through its enzymatic activity, but also
by other mechanisms as discussed above, independentlyV-PL-VIIIa pre-incubated with or without p-Bromophenacyl bromide.
entration of p-Bromophenacyl bromide (6 μM) at 37 °C for 15 min and
clear zone was measured and plotted after subtracting the diameter of
ssays, each performed in triplicate
Table 3 Antibacterial activity of VRV-PL-VIIIa with or without
p-Bromophenacyl bromide (p-BPB)
Microorganisms Diameter of inhibition zone (mm)
VRV-PL-VIIIa VRV-PL-VIIIa + p-BPB
Gram-positive
Staphylococcus aureus 32 ± 1 23 ± 3
Bacillus subtilis 27 ± 4 19 ± 1
Gram-negative
Escherichia coli 21 ± 2 13 ± 1
Salmonella typhi 16 ± 1 10 ± 3
Vibrio cholerae 16 ± 3 15 ± 2
Klebsiella pneumoniae 22 ± 2 14 ± 2
Salmonella paratyphi 21 ± 6 13 ± 3
The results are expressed as mean ± SD (n = 6)
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molecular mechanism of action of VRV-PL-VIIIa anti-
bacterial activity would be of interest to develop this as
a therapeutic lead molecule for application.Conclusion
This study shows that VRV-PL-VIIIa – a PLA2 from
Daboia russelii pulchella venom – presents potent anti-
bacterial activity. Significant antibacterial activity is
observed, even in presence of an inhibitor of PLA2
enzymatic activity (p-BPB), suggesting a dissociation or
partial overlapping of the bactericidal/antimicrobial do-
mains of the enzyme. This study demonstrates that
although there is a strong correlation between enzym-
atic and antimicrobial activities of VRV-PL-VIIIa, it
may also possess other properties that mimic the bac-
tericidal/membrane permeability-increasing protein.
These results should encourage further in-depth studies
on molecular mechanisms of anti-bacterial properties
of VRV-PL-VIIIa, which would thereby facilitate its
development into a therapeutic lead molecule for treat-
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